Shear Wave Elastograph and Contrast Enhanced Ultrasound for the Treatment of Lymphedema

Overview

Información sobre este estudio

Lymphaticovenous anstomosis is an effective surgery to treat lymphedema in the upper extremities secondary to cancer treatment. A crucial step is to identify patent lymphatic channels. Contrast enhanced ultrasound (CEUS) with intradermal injection of microbubbles is a promising method for lymphatic mapping in the upper extrmeities with lymphedema. The goals of the study are(1) to establish the preferred FDA approved microbubble agent (Lumason, Optison, Definity) for CEUS lymphatic mapping, (2) to identify lymphatic channels with CEUS and high-frequency ultrasound in patients receiving lymphaticovenous anastomosis surgery for upper extremity lymphedema, (3) and to validate the use of shear wave elastography for detecting improving in lymphedema prospectively.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

  • ≥ 18 years age.
  • Biological female.
  • Unilateral lymphedema in the upper extremity (ISL stage 2 or 3) secondary to breast cancer or breast cancer treatment.
  • Patient qualifies for LVA surgery as determined by the plastic surgeons performing the surgery (Dr. Bill Tran or Dr. Vahe Fahradyan), and the patient consents to surgery.
  • Patient must be able to come to the 6-month clinical follow-up appointment (Part 2 only).
  • Patients must be able to understand the study procedures and comply with them for the entire length of the study.
  • No contraception is necessary or required.

Exclusion Criteria:

  • Pregnant or nursing women.
  • Known or suspected hypersensitivity to microbubble contrast agent, perflutren, blood products, albumin, polyethylene glycol (PEG), or egg.
  • Known or suspected cardiac shunts.
  • Prior lymphedema surgery in the upper extremity.
  • Tattoo or scar on either upper extremity.
  • Current drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements.
  • Inability or unwillingness of individual or legal guardian/representative to give written informed consent..
  • Current or past participation within a specified timeframe in another clinical trial, as warranted by the administration of this intervention.

Eligibility last updated 6/24/22. Questions regarding updates should be directed to the study team contact.

 

 

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

Christine Lee, M.D., Ph.D.

Cerrado para la inscripción

Contact information:

Breast Melanoma Oncology Research

(507) 538-4849

BMSORESEARCH@mayo.edu

More information

Publicaciones

Publications are currently not available
.
CLS-20542776

Mayo Clinic Footer